Fujita A, Takabatake H, Tagaki S, Sekine K
Division of Respiratory Diseases, Minami-ichijo Hospital.
Gan To Kagaku Ryoho. 1995 Jun;22(7):889-93.
Sixteen patients with refractory small cell lung cancer (SCLC) were treated with an irinotecan starting dose of 100 mg/m2 given as a 90-minute iv infusion every week with subsequent doses based on toxicity. Mean age was 64 years; 14 male and 2 female; 4 with limited disease and 12 with extensive disease; all patients pretreated with combination chemotherapy containing etoposide. The overall response rate was 50% (95% CI 25-75%) with no CR and 8 PR. The median duration of response was 46 days. Major toxicities were leukopenia, diarrhea and pulmonary toxicity. Irinotecan was thus an effective agent in refractory SCLC.
16例难治性小细胞肺癌（SCLC）患者接受了伊立替康治疗，起始剂量为100mg/m²，每周静脉输注90分钟，后续剂量根据毒性调整。平均年龄64岁；男性14例，女性2例；4例为局限性疾病，12例为广泛性疾病；所有患者均接受过含依托泊苷的联合化疗预处理。总缓解率为50%（95%CI 25-75%），无完全缓解（CR），部分缓解（PR）8例。缓解持续时间中位数为46天。主要毒性为白细胞减少、腹泻和肺部毒性。因此，伊立替康是治疗难治性SCLC的有效药物。
